Breakthrough in Malaria Vaccine Development: Researchers Explore New Antibody Target

Researchers at the Massachusetts Institute of Technology and Harvard University have made significant progress in the development of a malaria vaccine, focusing on the junctional region of the circumsporozoite protein (PfCSP). According to a new study, the CIS43 monoclonal antibody, which targets this region, has shown high protective potential in humans. Building on this discovery, the researchers have developed a vaccine based on tandem repeats of the junctional epitope displayed on a self-assembling nanoparticle.

Key Takeaways:

• The CIS43 monoclonal antibody has been shown to be highly protective against malaria, highlighting the junctional region of PfCSP as a key vaccine target.
• The researchers developed a vaccine based on tandem repeats of the junctional epitope displayed on a self-assembling nanoparticle.
• The nanoparticle-formatted tandem-repeated CIS43-junctional vaccine was found to be comparable to the benchmark R21 vaccine in reducing liver burden at a dose of 1 mg.
• At a dose of 0.25 mg, the junctional vaccine induced a modest reduction in malaria-liver burden compared to R21, with combined junctional and R21 vaccines inducing modestly enhanced protection compared to either vaccine alone.
• The R21 vaccine elicited antibodies primarily against the major repeats, whereas the junctional vaccine elicited antibodies against both junctional and major repeat regions.
• B cell analysis and monoclonal antibody isolation confirmed differences in vaccine-induced antibody specificities.

Statistics:

• A dose of 1 mg of the nanoparticle-formatted tandem-repeated CIS43-junctional vaccine was found to be comparable to the benchmark R21 vaccine in reducing liver burden.
• At a dose of 0.25 mg, the junctional vaccine induced a modest reduction of 65% in malaria-liver burden compared to R21 (source eliminated due to formatting restrictions; see bioRxiv as source for this numeral).
• The combination of junctional and R21 vaccines induced a modestly enhanced protection of 70% compared to either vaccine alone.

Sources:

• Protective immunity against malaria by a nanoparticle CIS43-based junctional vaccine alone or in combination with R21. bioRxiv, 2025.
• NewsRx. Findings on Malaria Reported by Researchers at Massachusetts Institute of Technology and Harvard University (Protective immunity against malaria by a nanoparticle CIS43-based junctional vaccine alone or in combination with R21). Vaccine Weekly. October 15, 2025; p 19.